Mural Oncology plc Ordinary Shares - MURA STOCK NEWS

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has granted stock options and restricted stock units to a newly hired employee. The company issued non-statutory stock options to purchase 21,500 ordinary shares and restricted stock units for 11,500 ordinary shares. These grants were made under Mural's 2024 Inducement Stock Option and Incentive Plan, in compliance with Nasdaq Listing Rule 5635(c)(4).

The stock options have an exercise price of $3.16 per share, equal to the closing price on September 3, 2024. They have a ten-year term and vest over four years, with 25% vesting after one year and 6.25% quarterly thereafter. The restricted stock units also vest over four years, with 25% vesting annually. Both grants are subject to continued employment and specific award agreements.

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, has announced its participation in two upcoming investor conferences. The company, which develops novel engineered cytokine therapies for cancer patients, will be represented by key management team members at these events:

1. Morgan Stanley 22nd Annual Global Healthcare Conference on September 6 at 1:50 p.m. ET, featuring a fireside chat with CEO Caroline Loew, Ph.D., Chief Medical Officer Vicki Goodman, MD, and CFO Adam Cutler.

2. H.C. Wainwright 26th Annual Global Investment Conference on September 11 at 9:30 a.m. ET, where CEO Caroline Loew, Ph.D. will give a presentation.

Webcasts of both presentations will be available on the company's investor relations website. The management team will also be available for one-on-one meetings during these conferences.

Mural Oncology (Nasdaq: MURA) reported Q2 2024 financial results and provided a pipeline update. Key highlights include:

Financial Position: Cash, cash equivalents, and marketable securities stood at $204.7 million as of June 30, 2024. The company reaffirms its cash runway into Q4 2025.

Pipeline Progress: Mural is on track to report readouts from two late-stage clinical trials of its lead asset, nemvaleukin alfa, in 1H 2025. The company presented data on less frequent dosing of nemvaleukin at ASCO in June. Candidate nominations for IL-18 and IL-12 programs are expected later this year.

Financial Results: R&D expenses decreased to $27.5 million in Q2 2024 from $42.5 million in Q2 2023. G&A expenses increased to $6.7 million from $4.7 million. Net loss narrowed to $31.6 million from $50.2 million year-over-year.

Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced on August 2, 2024, that it granted stock options and restricted stock units to a newly hired employee on August 1. The grants include:

1. Non-statutory stock options to purchase 13,000 ordinary shares
2. Restricted stock units for 7,000 ordinary shares

These grants were made under the company's 2024 Inducement Stock Option and Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $3.48 per share, equal to the closing price on August 1, 2024. They have a ten-year term and vest over four years. The restricted stock units also vest over four years, with 25% vesting annually.

Mural Oncology plc (Nasdaq: MURA) has appointed George Golumbeski, Ph.D., to its board of directors effective July 30, 2024. Dr. Golumbeski brings 30 years of leadership in business development, with extensive experience in strategic collaborations, M&A, licensing, and alliance management. He currently serves as a partner at DROIA Ventures and has held key positions at GRAIL, Celgene, Nabriva Therapeutics, Novartis Oncology, and Elan Biopharmaceuticals.

Mural Oncology, a clinical-stage immuno-oncology company, is developing engineered cytokine therapies for cancer treatment. The company has two potentially registrational studies reading out in the first half of 2025 and two preclinical programs approaching candidate nomination later this year. Dr. Golumbeski's appointment is expected to bring valuable expertise as Mural advances its current programs and explores potential partnerships.

Mural Oncology, a clinical-stage immuno-oncology company, announced on July 1, 2024, the granting of non-statutory stock options and restricted stock units under its 2024 Inducement Stock Option and Incentive Plan. The grants were made as inducements for four newly hired employees under Nasdaq Listing Rule 5635(c)(4). The stock options cover 15,470 ordinary shares at an exercise price of $3.11, with a ten-year term and a vesting schedule of four years. The restricted stock units cover 8,330 ordinary shares, also vesting over four years. Both grants are subject to the terms of respective award agreements and the company's 2024 Inducement Plan.

Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company, announced that CEO Caroline Loew, Ph.D., will present at the 14th Annual East Coast IDEAS Investor Conference on June 13 at 9:15 a.m. EST.

The company focuses on developing engineered cytokine therapies to address unmet needs in cancer treatment. A webcast of the presentation will be available at www.threepartadvisors.com/east-coast and ir.muraloncology.com.

Mural will also host one-on-one investor meetings during the conference.

Mural Oncology, a clinical-stage immuno-oncology company listed on Nasdaq under the ticker MURA, announced the granting of inducement stock options and restricted stock units to two new employees.

On June 3, 2024, the company awarded non-statutory stock options to purchase 7,995 ordinary shares and restricted stock units for 4,305 ordinary shares under the company's 2024 Inducement Stock Option and Incentive Plan. The options have an exercise price of $3.41 per share, matching the closing price on June 3, 2024, a ten-year term, and vest over four years with 25% vesting after the first year and 6.25% vesting quarterly thereafter. The restricted stock units vest at 25% annually over four years.

These grants were made as an inducement for the employees' new roles, complying with Nasdaq Listing Rule 5635(c)(4).

Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.

The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.

Preliminary data from ARTISTRY-6 cohorts are expected in 2025.